Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Reinitiating TNF Blockers after Tuberculosis Treatment

  |  

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

Reference

ADVERTISEMENT
SCROLL TO CONTINUE
  1. Ozguler Y, Hatemi G, Ugurlu S, et al. Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy. Rheumatol Int. 2016 Oct 3. [Epub ahead of print]. doi:10.1007/s00296-016-3575-3

Related Articles

    Remembering Etanercept & the Advent of the Biologic Era

    As a veteran rheumatologist, I remember the clinical trials of etanercept’s (Enbrel’s) efficacy. And when the drug was first approved in 1998, I participated in those clinical trials and realized the effectiveness was astonishing. It was easy to tell which patients were treated with etanercept vs. those who received placebo, even though both groups were…